Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Amalgamated Bank

Amalgamated Bank lessened its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 2.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 40,929 shares of the specialty pharmaceutical company’s stock after selling 877 shares during the quarter. Amalgamated Bank owned approximately 0.07% of Jazz Pharmaceuticals worth $5,034,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the company. Los Angeles Capital Management LLC boosted its position in shares of Jazz Pharmaceuticals by 558.6% in the third quarter. Los Angeles Capital Management LLC now owns 322,775 shares of the specialty pharmaceutical company’s stock worth $41,780,000 after acquiring an additional 273,764 shares during the last quarter. Pacer Advisors Inc. grew its stake in shares of Jazz Pharmaceuticals by 28.1% during the 4th quarter. Pacer Advisors Inc. now owns 1,023,706 shares of the specialty pharmaceutical company’s stock valued at $125,916,000 after buying an additional 224,865 shares during the period. Thompson Siegel & Walmsley LLC increased its holdings in shares of Jazz Pharmaceuticals by 242.8% during the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 270,574 shares of the specialty pharmaceutical company’s stock worth $35,023,000 after buying an additional 191,648 shares during the last quarter. Aristotle Capital Management LLC purchased a new position in shares of Jazz Pharmaceuticals in the 3rd quarter worth $22,748,000. Finally, Federated Hermes Inc. boosted its holdings in Jazz Pharmaceuticals by 1,105.6% in the third quarter. Federated Hermes Inc. now owns 123,635 shares of the specialty pharmaceutical company’s stock valued at $16,003,000 after acquiring an additional 113,380 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Piper Sandler raised their price objective on Jazz Pharmaceuticals from $171.00 to $188.00 and gave the stock an “overweight” rating in a report on Wednesday, March 20th. StockNews.com downgraded shares of Jazz Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 2nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $180.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, April 10th. UBS Group decreased their price target on shares of Jazz Pharmaceuticals from $135.00 to $131.00 and set a “neutral” rating for the company in a research report on Friday, March 1st. Finally, Royal Bank of Canada restated an “outperform” rating and set a $195.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, February 29th. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $192.75.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $109.65, for a total value of $548,250.00. Following the sale, the executive vice president now owns 36,629 shares in the company, valued at $4,016,369.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Jazz Pharmaceuticals news, CAO Patricia Carr sold 1,936 shares of the business’s stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $119.64, for a total transaction of $231,623.04. Following the sale, the chief accounting officer now owns 8,364 shares in the company, valued at approximately $1,000,668.96. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Neena M. Patil sold 5,000 shares of the stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $109.65, for a total value of $548,250.00. Following the completion of the sale, the executive vice president now owns 36,629 shares of the company’s stock, valued at approximately $4,016,369.85. The disclosure for this sale can be found here. 4.40% of the stock is currently owned by company insiders.

Jazz Pharmaceuticals Price Performance

JAZZ stock opened at $111.21 on Wednesday. The company has a market capitalization of $7.01 billion, a PE ratio of 22.93, a P/E/G ratio of 1.53 and a beta of 0.63. The company has a quick ratio of 1.90, a current ratio of 2.27 and a debt-to-equity ratio of 1.38. The stock’s 50 day moving average is $115.56 and its two-hundred day moving average is $120.62. Jazz Pharmaceuticals plc has a 52-week low of $103.01 and a 52-week high of $146.70.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Wednesday, February 28th. The specialty pharmaceutical company reported $4.40 earnings per share for the quarter, missing the consensus estimate of $4.44 by ($0.04). The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1.01 billion. Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. Analysts predict that Jazz Pharmaceuticals plc will post 16.24 earnings per share for the current fiscal year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.